米托蒽醌
医学
长春碱
药品
药理学
毒性
癌症
内科学
淋巴瘤
作用机理
肿瘤科
化疗
长春新碱
环磷酰胺
化学
体外
生物化学
作者
H Lenk,U Müller,S Tanneberger
出处
期刊:PubMed
日期:1987-11-01
卷期号:7 (6): 1257-64
被引量:14
摘要
Mitoxantrone is similar to Adriblastin in its mechanism of action and antitumor activity. Objective remissions were obtained in 20-30% pretreated patients and in 23-44% of untreated patients by single-drug treatment of patients suffering from metastatic breast cancer. The objective response rates to Mitoxantrone in combination with CTX, 5-FU, MTX, VCR, MMC. Prednimustine or Vindesine were 16-46% in treatment and 38-89% in primary treatment. Randomized studies comparing Mitoxantrone with Adriblastin in single-drug and combination treatment did not show any significant differences in efficacy. However, Mitoxantrone was significantly less toxic. Remission rates of between 24 and 54% were achieved by single-drug treatment in pretreated patients suffering from non-Hodgkin lymphoma. Mitoxantrone appears to be active in ovarian cancer, lung cancer and hepatocellular carcinoma.
科研通智能强力驱动
Strongly Powered by AbleSci AI